Inhaled Treprostinil for PAH: Open-label Extension

Phase 3

Withdrawn

• Conditions: Pulmonary Arterial Hypertension
• Interventions: Drug: inhaled treprostinil

• Registration Number: NCT01557660
• Lead Sponsor: United Therapeutics

Brief Summary

Open-label extension of RIN-PH-302.

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-03
• Study First Submitted: 2012-03-14
• Study First Submitted QC: 2012-03-15
• Study First Posted: 2012-03-19
• Last Update Submitted: 2012-03-23
• Last Update Posted: 2012-03-26
• Study Start: 2012-06
• Primary Completion: 2018-12
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
inhaled treprostinil	inhaled treprostinil	-

Primary Outcome Measures

Name	Time	Method
Long term safety of inhaled treprostinil	up to 5 years

Secondary Outcome Measures

Name	Time	Method
Six-minute walk distance	up to 5 years